Apparent diffusion coefficient histogram analysis stratifies progression-free survival in newly diagnosed bevacizumab-treated glioblastoma

American Journal of Neuroradiology

Volumn 32, Issue 5, 2011, Pages 882-889

  Pope, Whitney B ^a   Lai, A ^a   Mehta, R ^a   Kim, H J ^a   Qiao, J ^a   Young, J R ^a   Xue, X ^a   Goldin, J ^a   Brown, M S ^a   Nghiemphu, P L ^a   Tran, A ^a   Cloughesy, T F ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CONTROLLED STUDY; DIFFUSION COEFFICIENT; FEMALE; GLIOBLASTOMA; HISTOGRAM; HUMAN; KAPLAN MEIER METHOD; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROPORTIONAL HAZARDS MODEL; PROTEIN METHYLATION; RANK SUM TEST;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; BRAIN NEOPLASMS; CALIFORNIA; DATA INTERPRETATION, STATISTICAL; DIFFUSION MAGNETIC RESONANCE IMAGING; DISEASE-FREE SURVIVAL; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PREVALENCE; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 79955866104     PISSN: 01956108     EISSN: 1936959X     Source Type: Journal    
DOI: 10.3174/ajnr.A2385     Document Type: Article

References (29)

1. Norden AD, Drappatz J, Wen PY. Antiangiogenic therapies for high-grade glioma. Nat Rev Neurol 2009;5:610-20
2. Rahman R, Smith S, Rahman C, et al. Antiangiogenic therapy and mechanisms of tumor resistance in malignant glioma. J Oncol 2010;2010:251231. Epub 2010 Apr 11
3. Fischer I, Gagner JP, Law M, et al. Angiogenesis in gliomas: biology and molecular pathophysiology. Brain Pathol 2005;15:297-310
4. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009;27:4733-40. Epub 2009 Aug 31
5. Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2009;27:740-45
6. Lai A, Nghiemphu PL, Green RM, et al. Updated results of phase II trial of bevacizumab in combination with temozolomide and regional radiation therapy for upfront treatment of patients with newly-diagnosed glioblastoma multiforme. Neuro Oncol 2009;11:632
7. Pope WB, Lai A, Nghiemphu P, et al. MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology 2006;66:1258-60 (Pubitemid 43739717)
8. Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 2010;28:1963-72. Epub 2010 Mar 15
9. Clarke JL, Chang S. Pseudoprogression and pseudoresponse: challenges in brain tumor imaging. Curr Neurol Neurosci Rep 2009;9:241-46
10. Levin VA, Bidaut L, Hou P, et al. Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. Int J Radiat Oncol Biol Phys 2011;79:1487-95
11. Chamberlain MC. Pseudoprogression in glioblastoma. J Clin Oncol 2008;26: 4359, author reply 4359-60
12. Claes A, Wesseling P, Jeuken J, et al. Antiangiogenic compounds interfere with chemotherapy of brain tumors due to vessel normalization. Mol Cancer Ther 2008;7:71-78
13. Fukushima T, Takeshima H, Kataoka H. Anti-glioma therapy with temozolomide and status of the DNA-repair gene MGMT. Anticancer Res 2009;29:4845-54
14. Jung TY, Jung S, Moon KS, et al. Changes of the O6-methylguanine-DNA methyltransferase promoter methylation and MGMT protein expression after adjuvant treatment in glioblastoma. Oncol Rep 2010;23:1269-76
15. Zhang J, Stevens MF, Laughton CA, et al. Acquired resistance to temozolomide in glioma cell lines: molecular mechanisms and potential translational applications. Oncology 2010;78:103-14
16. Drabycz S, Roldan G, de Robles P, et al. An analysis of image texture, tumor location, and MGMT promoter methylation in glioblastoma using magnetic resonance imaging. Neuroimage 2010;49:1398-405
17. Ellingson BM, Malkin MG, Rand SD, et al. Validation of functional diffusion maps (fDMs) as a biomarker for human glioma cellularity. J Magn Reson Imaging 2010;31:538-48
18. Carlson MR, Pope WB, Horvath S, et al. Relationship between survival and edema in malignant gliomas: role of vascular endothelial growth factor and neuronal pentraxin 2. Clin Cancer Res 2007;13:2592-98 (Pubitemid 46788024)
19. Pope WB, Kim HJ, Huo J, et al. Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. Radiology 2009;252:182-89
20. Higano S, Yun X, Kumabe T, et al. Malignant astrocytic tumors: clinical importance of apparent diffusion coefficient in prediction of grade and prognosis. Radiology 2006;241:839-46 (Pubitemid 46190551)
21. Oh J, Henry RG, Pirzkall A, et al. Survival analysis in patients with glioblastoma multiforme: predictive value of choline-to-N-acetylaspartate index, apparent diffusion coefficient, and relative cerebral blood volume. J Magn Reson Imaging 2004;19:546-54 (Pubitemid 38619916)
22. Otsu N. A threshold selection method from gray-level histograms. IEEE Trans Syst Man Cybern B Cybern 1979;9:62-66
23. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352:997-1003 (Pubitemid 40349502)
24. Macdonald DR, Cascino TL, Schold SC Jr, et al. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990;8:1277-80 (Pubitemid 20195640)
25. Brandes AA, Franceschi E, Tosoni A, et al. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 2008;26:2192-97
26. Wong ET, Brem S. Antiangiogenesis treatment for glioblastoma multiforme: challenges and opportunities. J Natl Compr Canc Netw 2008;6:515-22 (Pubitemid 351760842)
27. Zhou Q, Guo P, Kruh GD, et al. Predicting human tumor drug concentrations from a preclinical pharmacokinetic model of temozolomide brain disposition. Clin Cancer Res 2007;13:4271-79 (Pubitemid 47105992)
28. Zeng QS, Li CF, Liu H, et al. Distinction between recurrent glioma and radiation injury using magnetic resonance spectroscopy in combination with diffusion- weighted imaging. Int J Radiat Oncol Biol Phys 2007;68:151-58 (Pubitemid 46589825)
29. Minamikawa S, Kono K, Nakayama K, et al. Glucocorticoid treatment of brain tumor patients: changes of apparent diffusion coefficient values measured by MR diffusion imaging. Neuroradiology 2004;46:805-11 (Pubitemid 39534607)